AIG beating estimates on strong underwriting and CVS raising its full-year outlook tell us the same thing: large, boring companies that provide everyday essentials are quietly growing profits. With economists expecting a soft July jobs report of only 83,0

Verdict

The defensive-rotation thesis is conceptually sound — insurance premiums and prescriptions hold up in recessions, and management at both companies has raised forward guidance — but the strategy's entry conditions are not yet triggered for either name. CVS is the weakest link: trading at $97.00, it sits 5.8% below its 20-day EMA at $102.66 with an RSI of 23.0, meaning the setup requires a significant reversal before it becomes actionable. AIG is closer, with price already above its 20-day EMA, but ADX at 10.1 is nowhere near the 20 threshold and the EMA crossover is still roughly $0.98 away. The 24-month AIG backtest is a major red flag: a 23% win rate across 13 trades with a 15.4% maximum drawdown, though that window captures a different regime than the positive 60-month result of 6.4% on just 2 trades. No robust parameter setup was established, so the live strategy carries no optimization benefit, and both samples are too thin for statistical confidence. **Conviction breakdown:** Thesis support scores 55 — the narrative is coherent but depends on a soft-landing scenario that a genuinely weak jobs print could derail into recession. Trade readiness scores 25 — critical entry conditions remain unmet across both names. Risk quality scores 45 — the 2:1 reward-to-risk framework is reasonable but the 44.8% expected basket drawdown and CVS's fat tails (kurtosis of 50.7) are sobering. Backtest evidence scores 30 — contradictory windows (positive over 60 months, negative over 24 months) with thin trade counts make this unreliable. Fundamentals trend scores 55 — AIG's deleveraging and revenue growth are real, but CVS's 0.44% net margin and deteriorating operating trend undercut the "growing profits" claim.

Trade now

**AIG is the closest name to actionable, but it is not there yet.** The stock closed at $79.64, already above its 20-day EMA at $79.10, so that condition is met. However, the EMA 20 has not crossed above the EMA 50 ($78.11) — it is close, about $1 away — and ADX sits at just 10.1, needing to clear both 18 and 20 before the trend-strength gate passes. In other words, two of four entry conditions for AIG remain unmet, with ADX the furthest from triggering. **CVS is further from entry.** The stock closed at $97.00, trading below its 20-day EMA at $102.66 — about $5.67 short of that condition — and the EMA 20/50 crossover is not in place either, with the 20-day sitting well above the 50-day at $95.41. ADX is strong at 56.3, so trend strength is already met on the CVS side, but the price and crossover conditions are both far from triggering. **Risk parameters are defined.** The strategy runs a fixed stop at -2.4% and a take-profit at +4.8%, producing an effective reward-to-risk of roughly 2:1. Additional structural exits include a close below the second-ranked support level and a Fibonacci 127.2% extension target, whichever comes first. "Wait" here is concrete: monitor AIG daily for its EMA 20 to cross above EMA 50 and for ADX to climb above 20, while watching for CVS to recover above its 20-day EMA near $102.66. **Backtest context.** The 60-month AIG window produced a 6.4% return across two trades with a 50% win rate and a maximum drawdown of 10.4%. The 24-month AIG window was weaker, losing 2.1% across 13 trades with a 23.1% win rate and a 15.4% drawdown — a reminder that the signal environment matters and entries taken without sufficient trend confirmation carry higher risk.

Why the defensive-growth thesis has legs

The thesis rests on a simple but durable premise: in a softening labor market — with the CNBC piece on the July jobs report flagging expectations for just 83,000 new positions and unemployment at 4.2% — investors rotate into companies selling non-discretionary essentials. AIG and CVS fit that mold. Insurance premiums and prescription refills are among the last items households cut, and both companies just gave confirmation that the businesses are tracking the right way. Per the Bloomberg piece, AIG beat profit estimates citing strong underwriting, and the Yahoo Finance article reported CVS raising its 2026 outlook after stronger-than-expected second-quarter results. Those are not backward-looking data points; they are forward guidance from management. The fundamentals provide real support. AIG's revenue grew 2.96% year-over-year, placing it in the 81st percentile among its Financials peers — hardly a stagnating franchise. Return on equity stands at 7.53%, and the balance sheet carries a debt-to-equity ratio of just 0.22, down meaningfully from 0.66 at the end of…

Scores

• Conviction score breakdown: 42
• Thesis support: 55
• Trade readiness: 25
• Risk quality: 45
• Backtest evidence: 30
• Fundamentals trend: 55

Watch items

• AIG — ADX (14)
• AIG — EMA (20) vs EMA (50)
• AIG — Price vs EMA (20)
• CVS — Price vs EMA (20)
• CVS — RSI (14)
• CVS — ADX (14)
• CVS — Price vs Support ($96.00)
• AIG — Price vs Support ($78.00)
• AIG — Price above EMA (20)
• AIG — EMA (20) crossed above EMA (50)
• AIG — ADX (14) above 20
• AIG — ADX (14) above 18